Content Type: Commentary & Opinion

Risk, Responsibility, and Generic Drugs

March 16, 2026

Regulating Homeopathic Products—A Century of Dilute Interest

March 16, 2026

Reputation and Precedent in the Bevacizumab Decision

March 16, 2026

The Watchman Saga—Closure at Last?

March 16, 2026

Using Real‐World Safety Data in Regulatory Approval Decisions: Sotagliflozin and the Risk of Diabetic Ketoacidosis

March 16, 2026

The Next Forum for Unraveling FDA Off-Label Marketing Rules: State and Federal Legislatures

March 16, 2026

The Regulatory Accountability Act of 2017—Implications for FDA Regulation and Public Health

March 16, 2026

Reforms to Accelerated Approval of New Medicines: Long Overdue

March 16, 2026

COVID-19 Antivirals Must Not Affect HIV Drug Supply

March 16, 2026

Conflict of Interest Disclosure in Early Education of Medical Students

March 16, 2026

Precision Medicine and the FDA’s Draft Guidance on Laboratory-Developed Tests

March 16, 2026

Underrepresentation of Older Adults in Cancer Trials

March 16, 2026